Browse by Medical Category
ALS Multidisciplinary Clinic
Wednesday, February 14, 2018 Mass General
Wednesday, December 6, 2017 Research
Monday, July 10, 2017 Mass General
Monday, May 15, 2017 Clinical
Monday, May 8, 2017 Clinical
Wednesday, September 28, 2016 Research
Thursday, August 18, 2016 Research
Wednesday, September 9, 2015 Mass General
Wednesday, July 22, 2015 Mass General
Monday, July 13, 2015 Research
Tuesday, May 12, 2015 Research
Friday, August 15, 2014 Mass General
Friday, January 31, 2014 Research
Thursday, January 30, 2014 Clinical
Thursday, January 30, 2014 Research
Sunday, December 1, 2013 Mass General
Saturday, September 15, 2018
Friday, May 18, 2018
Monday, July 17, 2017
Thursday, July 13, 2017
Wednesday, June 28, 2017
Friday, May 12, 2017
Saturday, May 9, 2015
Sunday, January 1, 2012
View NEALS ALS Webinars
A webinar recording explaining the design and scientific rationale behind the Clinical Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease.
A video explaining the design and scientific rationale behind the Clinical Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease.
Neurology Bicentennial Celebration, October 13, 2011. Past History of MGH Neurology; Overview of MGH Neurology; Telestroke and Acute Stroke Service; Neurodegenerative Disorders; Pediatric Neurology.
Neurology Bicentennial Celebration, October 13, 2011. Clinical and research presentations on ALS, Stroke, Alzheimer’s Disease, and Parkinson’s Disease
A video for ALS patients discussing and demonstrating uses of bipap and cough assist machines.
Nicole from Boston, shares her story about her battle with ALS and her strong desire to help others with the disease in the future. Mass General's ALS Multidisciplinary Clinic provides the latest treatments and research opportunities for people with Amyotrophic Lateral Sclerosis.
Dr. Merit Cudkowicz, Neurology's Chief of Service, shares what makes the Mass General ALS Multidisciplinary Clinic so special.
Congratulations to Dr. Merit Cudkowicz, MGH Neurology Department Chairperson and Director, MGH ALS Clinic, for receiving the MDA LOU GEHRIG HUMANITARIAN AWARD. This award is given to a researcher, physician, or clinician who supports MDA/ALS research initiatives and clinical services and continues to fight the battle against ALS. View her acceptance speech where she discusses reasons for hope in the future of ALS treatments.
Learn how the Walk of Hope, sponsored by the ALS Raising Hope Foundation (www.alsraisinghope.org) raises funds for neurodegenerative disease research at MIND-and how researchers are using it to find cures.
Learn why MGH ALS researchers have hope for a cure and the research they are undertaking to find it.
The webinar features a presentation from senior leaders at MT Pharma America on RADICAVA's final label as approved by the FDA, as well as the patient access program we will be launching closer to product availability.
August 23, 2017 ALS Webinar
Watch MGH physicians Tim Ferris, MD, Merit Cudkowicz, MD, and James Berry, MD speak at the ALS House Call program launch event.
The “After Lunch Series” of webinars are a new initiative, led by the MGH-ALS Nurses, to provide a forum for discussion about common interventions and treatments for people living with ALS. The first webinar titled “G-Tube Talk” was held on Friday, May 18th from 1:30-2:30 pm. This webinar, and future ones, will be available on our website to be used as a resource and teaching tool by anyone living with ALS or helping someone who is living with ALS.
August 23, 2018 ALS Webinar
Watch presentations on the newest updates in ALS patient and caregiver clinical care and research.
Innovations in ALS Clinical Trials at Mass General
Dr. Merit Cudkowicz, Chief of Neurology at Mass General Hospital discusses innovations in ALS clinical trials since she started in the field in 1994.
Biomarkers to Accelerate ALS Therapy Development
Dr. Merit Cudkowicz, Chief of Neurology, discusses biomarkers that can help to diagnose patients quicker and target individualized treatments to patients.
Back to Top